Samonigg H, Fereberger W, Steindorfer P
Wien Klin Wochenschr. 1982 Apr 2;94(7):172-6.
Only between 0.5 and 1.2% of all breast cancers are found in men. Over the past 20 years 17 male breast cancers were treated in the University Clinic of Graz/Austria. Seven of these cases had localized disease and primary surgical treatment was performed; three out of the seven are still alive and show disease-free intervals of 2, 6 and 10 years, respectively. The metastatic cases were treated by various combinations of surgical treatment, radiotherapy, hormonal treatment and chemotherapy. Our results confirm the numerous communications in the literature that the therapeutic approach to male breast cancer is not essentially different to the management of female breast cancer at potentially curable stages. Primary orchidectomy still holds a dominant position in metastatic stages. Nevertheless, hormonal treatment with anti-oestrogens achieved an overall response rate of nearly 50%, which is comparable to the results with primary orchidectomy. Hence, this treatment is becoming of increasing importance as the primary form of treatment in hormone-sensitive metastatic male breast cancer.
在所有乳腺癌病例中，只有0.5%至1.2%发生在男性身上。在过去20年里，奥地利格拉茨大学诊所共治疗了17例男性乳腺癌患者。其中7例为局限性疾病，接受了初次手术治疗；这7例中有3例仍存活，分别有2年、6年和10年的无病生存期。转移性病例则采用了手术治疗、放疗、激素治疗和化疗等多种联合治疗方法。我们的结果证实了文献中的众多报道，即在潜在可治愈阶段，男性乳腺癌的治疗方法与女性乳腺癌的管理方法并无本质区别。在转移性阶段，原发性睾丸切除术仍占据主导地位。然而，抗雌激素激素治疗的总体缓解率接近50%，这与原发性睾丸切除术的结果相当。因此，这种治疗作为激素敏感型转移性男性乳腺癌的主要治疗形式正变得越来越重要。
